There were 208 medical clerkship students at Soebandi General Hospital that were assessed for COVID-19 vaccine eligibility. Amongst them, 44 (21 %) were excluded. We divided the excluded respondents into three groups. The first group, 10 clerkship students (4 %) were excluded because of not meeting the criteria of vaccination like hypertension, asthma exacerbation, diabetes, immuno-compromized and have a history of being COVID-19 positive in the past three months. The second group consists of 30 clerkship students (14 %) who declined to participate. The third group is 4 clerkship students (2 %) who were excluded due to other reasons. All included respondents were requested to fill the questionnaire to assess AEFI symptoms after vaccination.
The second follow-up began after booster vaccination. Overall, 16 out of the respondents could not be analyzed due to the loss of follow-up for the second questionnaire. We found four duplication data from all the respondents; this might happen if they fill the questionnaire twice or internet error. Total 144 medical clerkship students undergo the vaccination and this study process. In this study, the 144 homogenous respondents were 38 (26 %) men and 106 (74 %) women, with an age range between 21 and 25 years old. Homogenous respondents means that all medical students who participate as samples have the same knowledge level, they are medical clerkship students who have gone through the same educational process by completing the undergraduate stage. The respondents enrollment process is shown in Fig. 1.
We identified the AEFI’s report between the first and booster (Fig. 2). In the first dose, we found 55 (38 %) respondents that were reporting symptoms that indicate an AEFI. While in the booster dose, we found 51 (35 %) respondents that were reporting symptoms that indicate an AEFI.
Based on gender, we analyzed using a comparison study between the man and woman group with the correlation of AEFI using Chi-Square test. We found no difference between the man and woman groups to the AEFI (p-value = 0.983, IC = 95 %). The graphic between gender and the development of AEFI is shown in Fig. 3.
We analyzed the typical symptoms that have been reported. There were systemic and localized effects. The systemic symptoms show a total of 36 reports in the first dose vaccination and 40 reports in the booster dose, while the localized symptoms show a total of 33 reports in the first dose vaccination and 44 reports in the booster dose. As mentioned in Fig. 4, the most common systemic AEFI symptoms of COVID-19 vaccinations was malaise with 20 (36 %) reports in the first dose and 21 (41 %) reports in the booster dose. The other types of symptoms that have been reported were: headache, fever, shivering, sleepiness, nausea, dysphagia, and cold.
While for localized effect, as mentioned in Fig. 5, the most common localized AEFI symptoms of COVID-19 vaccinations was localized pain in the injection site during the first dose with 25 (45 %) reports and booster dose with 34 (67 %) reports. Then followed by malaise, the first dose with 20 (36 %) reports or booster dose with 21 (41 %) reports. The other types of symptoms that have been reported were localized skin swollen, the first dose with 3 (5 %) reports and booster dose with 1 (2 %) report; localized skin redness during the first dose with 3 (5 %) reports and booster dose with 6 (12 %) reports; and localized skin itchy, the first dose with 2 (4 %) reports, and the booster dose with 1 (2 %) report.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.